FilingsTodayGuardant Health
At a glance
Guardant Health reported 2025 revenue of $982M, up 32.9% from $739M in 2024. Over 4 years since 2021 ($373.7M), that is growth of about 27.3% a year. Operating margin was -44.5%, up from -110% in 2021. 2025 was the highest revenue year in this period. The company posted a loss in 2021, 2022, 2023, 2024 and 2025.
In the last 12 months 15 insiders reported 1 open-market purchase ($78K) and 56 sales ($173.9M). 24 of the sales were made under pre-arranged 10b5-1 plans. The largest was a sale of $39.3M by Co-Chief Executive Officer Amirali Talasaz on Jun 30, 2026. Net, insiders were sellers of $173.9M.
Guardant Health filed 7 current reports (Form 8-K) in the last 12 months, most often for results of operations (4), shareholder vote results (1), officer or director change (1) and material agreement (1). The latest officer or director change was reported on Apr 27, 2026. It reported a material agreement or a completed acquisition or disposal 1 time.
2 of the 20 investors tracked here held Guardant Health at the last quarter end, worth $76.6M combined. It is the largest weight for ARK Investment Management (0.5% of its portfolio), followed by Bridgewater Associates (0%). Added: ARK Investment Management. Reduced: Bridgewater Associates.
Annual results
| Year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Net income | -$384.8M | -$654.6M | -$479.4M | -$436.4M | -$416.3M |
| Diluted EPS | $-4.00 | $-6.41 | $-4.28 | $-3.56 | $-3.32 |
Fiscal year ends Dec 31 · incorporated in DE
Tracked investors holding (13F)
Weight is the share of each investor's portfolio, as of the quarter end.
Current reports (8-K, last 12 months)
Insider open-market trades (last 12 months)
Source: SEC EDGAR. How figures are combined